Zinacef

Impetigo, Maxillary Sinusitis, Bacterial Meningitis + 17 more

Treatment

2 FDA approvals

20 Active Studies for Zinacef

What is Zinacef

Cefuroxime

The Generic name of this drug

Treatment Summary

Ceftriaxone is a broad-spectrum antibiotic used to treat bacterial infections caused by both gram-positive and gram-negative organisms. It is especially effective against gonorrhea and Haemophilus infections, and is resistant to beta-lactamase enzymes.

Zinacef

is the brand name

Zinacef Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zinacef

Cefuroxime

1989

163

Approved as Treatment by the FDA

Cefuroxime, commonly known as Zinacef, is approved by the FDA for 2 uses such as Bacterial Infections and Urinary Tract Infection (UTI) .

Bacterial Infections

Urinary Tract Infection (UTI)

Effectiveness

How Zinacef Affects Patients

Cefuroxime is an antibiotic that works by blocking bacteria from forming the walls they need to survive. This makes it a "bactericidal" drug. Cefuroxime has been shown to be effective against many types of bacteria including Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, and Neisseria gonorrhoeae. It is also effective against Borrelia burgdorferi, which is a type of bacteria that causes Lyme disease. Cefuroxime axet

How Zinacef works in the body

Cefuroxime is an antibiotic that works by interfering with the construction of bacteria's cell walls. It binds to proteins inside the cell wall, preventing the cell wall from being built correctly. As a result, the cell wall weakens and breaks apart, leading to the destruction of the bacterial cell.

When to interrupt dosage

The suggested dosage of Zinacef is contingent upon the determined condition, including Gonorrhea, Urinary Tract Infection (UTI) and Bone and Joint Infections. The measure of dosage fluctuates in accordance with the method of administration (e.g. Intravenous or Tablet, film coated) outlined in the table below.

Condition

Dosage

Administration

Maxillary Sinusitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

prophylaxis of infection in minor cuts, scrapes, or burns

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Animal bite

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Bacterial Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

mild Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

moderate Streptococcal tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Urinary Tract Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Osteomyelitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Bronchitis, Chronic

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Otitis Media

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Septicemia

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Urinary Tract Infection (UTI)

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Impetigo

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Bacterial Meningitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

moderate Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Operative Surgery

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Gonorrhea

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Lyme Disease

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Bronchitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Suspension - Oral, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Powder - Oral, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder

Warnings

Zinacef Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Zinacef.

Common Zinacef Drug Interactions

Drug Name

Risk Level

Description

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Neomycin.

Tenofovir

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir disoproxil.

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefuroxime.

Zinacef Toxicity & Overdose Risk

Taking too much of a cephalosporin can cause an allergic reaction, with symptoms such as rash, a stuffy nose, coughing, a sore throat, and eye irritation. In severe cases, anaphylactic shock may occur. Taking too much of a cephalosporin can also result in irritation of the brain, causing seizures.

image of a doctor in a lab doing drug, clinical research

Zinacef Novel Uses: Which Conditions Have a Clinical Trial Featuring Zinacef?

At present, 146 active clinical trials are being conducted to assess the capability of Zinacef in providing relief from moderate Streptococcal pharyngitis, Bacterial Infections and Animal bite.

Condition

Clinical Trials

Trial Phases

Gonorrhea

0 Actively Recruiting

Operative Surgery

68 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2

moderate Streptococcal pharyngitis

0 Actively Recruiting

prophylaxis of infection in minor cuts, scrapes, or burns

0 Actively Recruiting

Maxillary Sinusitis

0 Actively Recruiting

Septicemia

1 Actively Recruiting

Not Applicable

Tonsillitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

moderate Streptococcal tonsillitis

0 Actively Recruiting

Bronchitis

3 Actively Recruiting

Phase 3, Not Applicable

Lyme Disease

5 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3

Bacterial Meningitis

2 Actively Recruiting

Phase 2

Animal bite

0 Actively Recruiting

Otitis Media

0 Actively Recruiting

Impetigo

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

mild Streptococcal pharyngitis

0 Actively Recruiting

Urinary Tract Infections

15 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1, Phase 3

Osteomyelitis

0 Actively Recruiting

Urinary Tract Infection (UTI)

5 Actively Recruiting

Phase 1, Phase 3, Phase 4, Not Applicable

Patient Q&A Section about zinacef

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of antibiotic is Zinacef?

"This medication is an antibiotic that belongs to a class of drugs called cephalosporins. It works by stopping the growth of bacteria."

Answered by AI

What is Zinacef used for?

"Zinacef is an antibiotic that is used to treat a wide variety of bacterial infections. Zinacef can also be taken before and during certain surgeries to help prevent infection from occurring."

Answered by AI

Is Zinacef a penicillin?

"Cefuroxime is an antibiotic that is chemically similar to penicillin."

Answered by AI

Is cefuroxime a strong antibiotic?

"Do cefuroxime and amoxicillin treat similar types of infection? Both antibiotics are effective for the right scenario, but there are some types of infection where one may be better."

Answered by AI

Clinical Trials for Zinacef

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Image of MedStar National Rehabilitation Hospital in Washington D.C., United States.

Rapid UTI Diagnostics for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

Patients who seek care through MedStar National Rehab Hospital's clinic believing they have a UTI will be enrolled in this trial. They will be pre-screened after consent according to a standard-of-care clinical symptom measure called the USQNB. If determined by this measure to be at high or moderate likelihood of having a UTI, they will be assigned to the presumed UTI arm and instructed to come to the clinic to provide a urine sample and undergo standard diagnostic testing to determine if a UTI is present. Those not assigned to the presumed UTI arm at this phase are assigned to the presumed no UTI arm and do not present to the clinic. These tests include a repeated questionnaire about the UTI symptoms they are experiencing and collection of a urine sample from a freshly changed indwelling catheter for standard clinical urinalysis testing and culture. Based upon the clinical guideline-informed results of these standard clinical tests, patients will be assigned into one of two potential arms (suspected UTI or suspected non-UTI) based on whether or not they are diagnosed with UTI at that visit. Arm 1 (presumed UTI) participants will have a second urine sample collected at the time of the visit from the used indwelling catheter bag in addition to the freshly changed catheter sample, and both will be divided into three portions: one for repeat clinical tests and culture, one for assessment using the experimental Jiddu device, and one to be stored for potential future studies. The study doctor will then determine antibiotic choice according to standard clinical decision making and record, but not prescribe, that choice. Once results are obtained from the samples sent for experimental analysis, the study doctor will use those results in addition to their best clinical judgement and all standard available clinical evidence to choose the antibiotic treatment. Arm 1 participants will then complete urine symptom surveys at day 3 and 7 during antibiotic use to determine effectiveness of antibiotics prescribed. In the event of standard urine culture results differing from the Jiddu-produced pooled AST values rescue antibiotic consisting of the antibiotic choice based on best clinical judgement using this newly available evidence will be used to ensure safety and this survey clock will restart and include a USQNB on day 10. Arm 2 participants will repeat the urinary symptoms questionnaire 3 and 7 days after their initial completion to see if their symptoms have changed and would allow them to qualify. If they remain unqualified at 7 days, they will be instructed to fill out another survey the next time they think they have a UTI. This process will repeat until they either qualify to become an Arm 1 participant or 6 months have passed since they first consented.

Waitlist Available
Has No Placebo

MedStar National Rehabilitation Hospital

Ana Valeria Aguirre Guemez, MD

Have you considered Zinacef clinical trials?

We made a collection of clinical trials featuring Zinacef, we think they might fit your search criteria.
Go to Trials

Have you considered Zinacef clinical trials?

We made a collection of clinical trials featuring Zinacef, we think they might fit your search criteria.
Go to Trials

Have you considered Zinacef clinical trials?

We made a collection of clinical trials featuring Zinacef, we think they might fit your search criteria.
Go to Trials